The stock of Theravance Biopharma Inc (NASDAQ:TBPH) reached all time high today, Oct, 6 and still has $56.56 target or 55.00% above today’s $36.49 share price. This indicates more upside for the $1.80 billion company. This technical setup was reported by Barchart.com. If the $56.56 PT is reached, the company will be worth $990.00 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 31,388 shares traded hands. Theravance Biopharma Inc (NASDAQ:TBPH) has risen 110.95% since March 3, 2016 and is uptrending. It has outperformed by 102.60% the S&P500.
Analysts await Theravance Biopharma Inc (NASDAQ:TBPH) to report earnings on November, 14. They expect $-0.97 EPS, up 30.71% or $0.43 from last year’s $-1.4 per share. After $-1.06 actual EPS reported by Theravance Biopharma Inc for the previous quarter, Wall Street now forecasts -8.49% EPS growth.
Theravance Biopharma Inc (NASDAQ:TBPH) Ratings Coverage
Out of 3 analysts covering Theravance Biopharma (NASDAQ:TBPH), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Theravance Biopharma has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Evercore initiated it with “Buy” rating and $41 target price in Monday, August 29 report. Guggenheim initiated Theravance Biopharma Inc (NASDAQ:TBPH) on Monday, June 20 with “Buy” rating. The rating was maintained by Robert W. Baird with “Neutral” on Wednesday, August 12. The company was initiated on Thursday, May 12 by Leerink Swann.
According to Zacks Investment Research, “Theravance Biopharma, Inc. is a biopharmaceutical company. It is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (CNS)/pain, respiratory disease, and gastrointestinal (GI) motility dysfunction. Theravance Biopharma, Inc. is based in George Town, Cayman Islands.”
Insitutional Activity: The institutional sentiment increased to 3.32 in Q2 2016. Its up 1.98, from 1.34 in 2016Q1. The ratio increased, as 5 funds sold all Theravance Biopharma Inc shares owned while 14 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 48.58 million shares or 135.18% more from 20.66 million shares in 2016Q1.
The Washington-based Parametric Associate Ltd Liability has invested 0% in Theravance Biopharma Inc (NASDAQ:TBPH). Alliancebernstein Limited Partnership holds 57,839 shares or 0% of its portfolio. Barclays Plc holds 0% or 13,489 shares in its portfolio. State Board Of Administration Of Florida Retirement Systems holds 0% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH) for 25,478 shares. The Massachusetts-based Geode Capital Mgmt Lc has invested 0% in Theravance Biopharma Inc (NASDAQ:TBPH). Credit Suisse Ag accumulated 123,022 shares or 0% of the stock. Dimensional Fund Ltd Partnership accumulated 0% or 43,018 shares. Blackrock last reported 3,821 shares in the company. Moreover, California State Teachers Retirement Sys has 0% invested in Theravance Biopharma Inc (NASDAQ:TBPH) for 76,061 shares. The California-based Wells Fargo Communications Mn has invested 0% in Theravance Biopharma Inc (NASDAQ:TBPH). Swiss Fincl Bank reported 53,942 shares or 0% of all its holdings. Dekabank Deutsche Girozentrale last reported 0.01% of its portfolio in the stock. The Maryland-based Rock Springs Mgmt L P has invested 1.18% in Theravance Biopharma Inc (NASDAQ:TBPH). Comml Bank Of New York Mellon has invested 0% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH). Teachers Advsr Inc has 58,362 shares for 0% of their US portfolio.
Insider Transactions: Since August 18, 2016, the stock had 0 insider purchases, and 3 selling transactions for $1.74 million net activity. $1.35M worth of shares were sold by Shafer Bradford J on Thursday, August 18. HAUMANN BRETT K had sold 4,491 shares worth $125,703.
More recent Theravance Biopharma Inc (NASDAQ:TBPH) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on June 06, 2014. Also Fool.com published the news titled: “Why Theravance Biopharma Inc. Fell 20% in September” on October 24, 2015. Seekingalpha.com‘s news article titled: “Theravance Biopharma: Will The Outperformance Continue?” with publication date: August 10, 2016 was also an interesting one.
TBPH Company Profile
Theravance Biopharma, Inc. (Theravance Biopharma) is a biopharmaceutical company. The Firm is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Firm operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. The Company’s commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease (COPD). The Company’s neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Neprilysin (NEP) is an enzyme that degrades natriuretic peptides.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.